Similarly, the assessment of CD3+ or CD8+ cells was ascertained by multiplying the percentage they represent in the inflammatory cells of the tumor or tumor stroma by the score of inflammatory cells in the respective sample's tumor or tumor stroma. This evidence concerns the gene CD8A and neoplasm.